我国药品集团采购模式发展现状及市场化GPO路径探索

邵蓉; 谢金平; 王文睿; 陈缪丰; 甘石; 胡飞琴

doi:10.19546/j.issn.1674-3830.2023.3.003

中国医疗保险 ›› 2023, Vol. 0 ›› Issue (3) : 19-25. DOI: 10.19546/j.issn.1674-3830.2023.3.003

深度聚焦

我国药品集团采购模式发展现状及市场化GPO路径探索

邵蓉¹, 谢金平¹, 王文睿¹, 陈缪丰¹, 甘石², 胡飞琴²

作者信息 +

The Development Status of Chinese Drug Group Purchasing Model and the Exploration of Market-based GPO Path

Author information +

文章历史 +

摘要

本文采用文献研究、比较研究、访谈调研等研究方法,通过借鉴美国集团采购经验,详细剖析我国现有GPO模式运行现状,并结合我国医药行业国情,提出了我国探索市场化GPO的发展路径。我国政府应当首先扶持社会化GPO发展,让GPO扎根现有采购平台,不断健全运行规则,待环境成熟再逐步过渡至市场化GPO。GPO组织也应当不断完善组织架构、创新采购模式并提供优质的采购服务。同时还应当健全GPO行业监督,共同促进GPO发展,让采购工作真正有利于民。

Abstract

This study adopted research methods such as literature study, comparative study, and interview research. By referring to the experience of American group purchasing, this study analyzed the current situation of the operation of the existing GPO model in China in detail and proposed a development path for exploring market-based GPO in China, taking into account the conditions of China's pharmaceutical industry. The government could first support the development of social GPOs, relying on existing procurement platforms. In addition, the government should continue to improve the operating rules and gradually transit to market-based GPOs when the environment is mature. GPOs should also constantly improve their organizational structure, innovate procurement models, and provide high-quality procurement services. At the same time, GPO industry supervision should be improved to jointly promote the development of GPO, so that procurement is really beneficial to the people.

导出引用

邵蓉, 谢金平, 王文睿, 陈缪丰, 甘石, 胡飞琴. 我国药品集团采购模式发展现状及市场化GPO路径探索[J]. 中国医疗保险. 2023, 0(3): 19-25 https://doi.org/10.19546/j.issn.1674-3830.2023.3.003

The Development Status of Chinese Drug Group Purchasing Model and the Exploration of Market-based GPO Path[J]. China Health Insurance. 2023, 0(3): 19-25 https://doi.org/10.19546/j.issn.1674-3830.2023.3.003

中图分类号： F840.684 C913.7

参考文献

[1] 谢金平,王斌,陈缪丰,等.常州市第二批国家药品集中采购政策实施效果研究——基于双组间断时间序列分析[J].中国卫生政策研究,2022,15(05):59-66.
[2] 国务院办公厅.关于完善公立医院药品集中采购工作的指导意见[EB/OL].(2015-02-28)[2023-01-15]. http://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm.
[3] 王莹,焦明丽,姜巍.解构主义视角下美国百年GPO驱动因素、供应链分析及对我国的启示[J].中国卫生经济,2021,40(05):12-15.
[4] 谢金平,张雪瑞,张赫,等.典型发达国家药品采购模式研究及启示[J].卫生经济研究,2022,39(01):64-68.
[5] IBIS World. Group Purchasing Organizations in the US-Market Size2005-2027[EB/OL]. (2021-08-17)[2023-01-15]. https://www.ibisworld.com/industry-statistics/market-size/group-purchasing-organizations-united-states/.
[6] 张志慧. 美国集团采购与药品福利管理模式对比研究[J].中国医疗保险,2021(07):76-80.
[7] 邵蓉,谢金平,蒋蓉.美国集团采购组织分析及对我国药品采购的启示[J].中国卫生政策研究,2014,7(06):35-40.
[8] 丛鹂萱,陈珉惺,邹璇,等.美国集团采购组织核心要素介绍及与深圳模式对比分析[J].中国卫生经济,2019,38(12):113-116.
[9] JING J, JIAMEI X, YUE Y, et al.Group Purchasing Organizations (GPOs) in the US: Development and Reform[J].亚洲社会药学, 2019, 14(3): 100-109.
[10] OPOKU-AGYEMAN W, WEECH-MALDONADO R, UPADHYAY S, et al.Environmental and Organizational Factors Associated with Hospital Use of GPO Services[J]. Hospital Topics, 2020, 98(3): 89-102.
[11] 苏涛,常峰,邵蓉.对美国药品集中采购组织的解析[J].上海药,2011,32(06):295-297.
[12] Government Accountability Office. Group Purchasing Organizations: Federal Oversight and Self-Regulation[EB/OL]. (2012-03-30)[2022-05-05]. https://www.gao.gov/products/gao-12-399r.
[13] 王永利. 深圳药品集采GPO模式值得总结推广[J].中国经贸导刊,2021(10):26-28.